Emerging treatments
Colchicine
Several randomised control trials have investigated the role of the anti-inflammatory agent colchicine in both chronic and acute coronary syndromes.[7] Use of colchicine for secondary prevention was shown to significantly reduce composite cardiovascular end points (including cardiovascular death, myocardial infarction, and stroke) in two meta-analyses of trials investigating patients with a previous acute coronary event.[122][123] The European Society of Cardiology recommends that low-dose colchicine be considered for long-term management of patients with acute coronary syndrome on the basis of its anti-inflammatory properties, particularly if other risk factors are insufficiently controlled or recurrent cardiovascular events occur under optimal therapy.[7]
Use of this content is subject to our disclaimer